Yatharth Hospital & Trauma Care Services
Market cap ₹10,513 Cr
- P/E
- 55.19
- Day range
- ₹1,079.70 – ₹1,129.55
- 52-week range
- ₹538.25 – ₹1,184.00
- Volume
- 2.62 L
- Open
- ₹1,110.95
- Prev close
- ₹1,109.55
Latest results · Q2 FY27(consolidated)Revenue ₹431 Cr+54.4%Profit ₹48 Cr+17.5%Margin 11.2%YoY vs the same quarter last year
1 red flag to read up on
- medium
Promoter holding falling
55.80%, down 5.84 pts since 2025-09-30 · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
YATHARTH in NSE indices and F&O
Research profile
Composite 53 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.8%
- Graham no.
- ₹292.12
- vs Graham
- -73.2%
- ROE ÷ P/B
- 1.8%
- 12-1 mom.
- +26.5%
- Return / vol
- 1.07
- Magic Formula
- #509
- Piotroski
- 2/6
- FCF yield
- -1.0%
- PEG
- 3.21
Appears in 13 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Yatharth Hospital & Trauma Care ServicesYATHARTH | ₹10,513 Cr | 55.19 | 5.69 | 10.0% | 13.0% | 24.0% | 0.25 | +54.5% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 8h agoHeadlines about Yatharth Hospital & Trauma Care Services from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 56.1
- Price / Book
- 5.60
- ROE (FY26)
- 10.0%
- ROCE (latest year)
- 13%
- Dividend yield
- 0.05%
Moving averages (NSE)
- 20-day
- ₹991.1
- Price above
- 50-day
- ₹1,017.98
- Price above
- 200-day
- ₹837.91
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- DII
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 167 | 178 | 212 | 218 | 219 | 232 | 258 | 279 | 320 | 342 | 393 | 431 |
| Expenses | 120 | 131 | 158 | 163 | 164 | 175 | 193 | 215 | 246 | 262 | 301 | 329 |
| Operating Profit | 46 | 47 | 54 | 55 | 55 | 57 | 64 | 65 | 74 | 80 | 92 | 102 |
| OPM % | 28% | 26% | 25% | 25% | 25% | 25% | 25% | 23% | 23% | 23% | 23% | 24% |
| Other Income | 5 | 6 | 4 | 3 | 4 | 5 | 9 | 9 | 8 | 7 | 4 | 5 |
| Interest | 0 | 0 | 3 | 2 | 2 | 1 | 0 | 0 | 1 | 5 | 7 | 8 |
| Depreciation | 8 | 8 | 11 | 16 | 17 | 13 | 15 | 19 | 24 | 30 | 28 | 33 |
| Profit before tax | 44 | 44 | 43 | 40 | 40 | 49 | 59 | 55 | 57 | 52 | 61 | 66 |
| Tax % | 33% | 13% | 29% | 23% | 24% | 20% | 28% | 25% | 25% | 14% | 26% | 26% |
| Net Profit | 29 | 38 | 30 | 31 | 30 | 39 | 42 | 41 | 43 | 45 | 45 | 48 |
| EPS in Rs | ₹3.44 | ₹4.47 | ₹3.54 | ₹3.61 | ₹3.16 | ₹4.02 | ₹4.36 | ₹4.28 | ₹4.71 | ₹4.93 | ₹4.88 | ₹5.25 |
From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+51 days since Mar 2021
-11 days since Mar 2025
+111 days since Mar 2025
-88 days since Mar 2021
+98 days since Mar 2021
Strengths, risks & growth
Incorporated in 2008, Yatharth Hospital and Trauma Care Services Limited is a multi-care hospitals at Noida, Greater Noida, and Noida Extension, Uttar Pradesh. [1]
Strengths
- Company is expected to give good quarter
- Company has delivered good profit growth of 57.1% CAGR over last 5 years
- Company's working capital requirements have reduced from 101 days to 80.1 days
Risks
- Company has a low return on equity of 12.1% over last 3 years.
- Promoter holding has decreased over last 3 years: -10.5%
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +41%
- 3 Years
- +36%
- TTM
- +50%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +57%
- 3 Years
- +38%
- TTM
- +25%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- +42%
- 1 Year
- +40%
Return on Equity
- 10 Years
- +14%
- 5 Years
- +14%
- 3 Years
- +12%
- Last Year
- +10%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 55.80% | 55.80% | 55.80% | 55.80% | 0.00 pp |
| FII | 6.18% | 5.25% | 5.62% | 7.05% | +1.43 pp |
| DII | 11.02% | 12.00% | 10.84% | 10.94% | +0.10 pp |
| Public | 27.01% | 26.94% | 27.74% | 26.21% | -1.53 pp |
Filed with NSE for Sept 2026: promoters 55.80%, public 44.20%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 9.56% (-0.18 pp)- Promoters55.8%
- Foreign institutions7.0%
- Mutual funds9.6%
- Insurance0.2%
- Other domestic institutions1.2%
- Retail14.0%
- Others12.2%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Bandhan Small Cap Fund | 3.43% | 1.04% | -0.03 pp |
| Kotak Multi Cap Fund | 2.73% | 0.98% | +0.10 pp |
| Kotak Balanced Advantage Fund | 0.96% | 0.62% | +0.10 pp |
| Kotak Special Opportunities Fund | 0.27% | 1.59% | -0.12 pp |
| Groww Multicap Fund | 0.22% | 1.23% | -0.59 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 291 daily sessions to 17 Nov 2026.
Risk
- Volatility (1Y)
- 38.7%
- Downside volatility
- 34.8%
- Worst 5% of days
- 3.6%
- Average of that tail
- 4.8%
- Max drawdown (1Y)
- 33.8%
- Below its peak
- 4.5%
Against the market
- Beta vs Nifty 50
- 0.83
- Correlation
- 0.29
- Relative strength (3M)
- +27.2%
- ATR (14)
- 3.6%
Return
- Return 1M
- +11.9%
- Return 3M
- +31.4%
- Return 6M
- +36.0%
- Return 1Y
- +41.6%
- vs 200-day average
- +32.4%
Momentum
- RSI (14)
- 70.0
- MACD histogram
- 14.89
- Stochastic %K
- 93.7
- ADX (14)
- 25.1
- +DI / −DI
- 32.0 / 12.7
- Money flow index
- 82.2
Participation
- Delivery (20d avg)
- 39.0%
- vs its 60-day baseline
- -0.7 pts
- Volume vs 20-day
- +0.5σ
- Close vs day's VWAP
- +0.1%
- 52-week position
- 91 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
2 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — passed
- Free cash flow
- -₹112 Cr
- FCF yield
- -1.0%
- Cash conversion
- 1.20
- Accruals ratio
- -0.015
- Net debt
- ₹193 Cr
- Net debt / equity
- 0.10
- EV / sales
- 7.32
- PEG
- 3.21
- Capex intensity
- 26.4%
- Revenue CAGR
- 51.3%
- Profit CAGR
- 16.1%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividendNot available — not reported in this filing
Interim Dividend - Re 0.50 Per Share
14 Aug 2026ex-date - otherNot available — not reported in this filing
Annual General Meeting
21 Sept 2023ex-date
Company announcements
We hereby submit Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for Q2FY27.
We hereby submit Newspaper Publication for the Corrigendum to the Notice of the 1st/2026-27 Extra-Ordinary General Meeting of the Company.
We hereby submit Corrigendum to the Notice of the 1st/2026-27 Extra-Ordinary General Meeting to be held on October 15, 2026.
We hereby submit intimation regarding the Closure of Trading Window for Q2FY27.
We hereby submit the Scrutinizer's Report of 19th Annual General Meeting of the Company held on September 25, 2026.
We hereby submit the Voting Results of the 19th Annual General Meeting of the Company held on September 25, 2026.
We hereby submit the summary of the Proceedings of 19th Annual General Meeting of the Company held today i.e. September 25, 2026.
We hereby submit intimation regarding Schedule of Analyst/Investor Meet.
We hereby submit the Newspaper Publication of the Notice for the 1st/2026-27 Extra-Ordinary General Meeting of the Company along with the e-voting information.
We hereby submit Notice of 1st/2026-27 Extra-Ordinary General Meeting of the Company.
We hereby submit intimation regarding amendments to Memorandum and Articles of Association.
We hereby submit Issuance and allotment of equity shares and warrants of the Company by way of preferential issue on a private placement basis.
We hereby submit Press Release
We hereby submit Outcome of Board Meeting held on September 17, 2026.
Yatharth Hospital & Trauma Care Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/09/2026 ,inter alia, to consider and approve Fund ....
Filed with BSE (scrip 543950); the last 45 days. Documents open at bseindia.com.
Documents
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- Aug 2026Slides
- Jun 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 6 Nov from crisil
- Rating update · 28 Sep from crisil
- Rating update · 20 May from crisil
- Rating update · 6 Nov 2025 from crisil
- Rating update · 23 Sep 2025 from crisil
- Rating update · 8 Nov 2024 from crisil
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Yatharth Hospital & Trauma Care Services: common questions
Answered from the figures on this page.